NL300757I1 - - Google Patents

Info

Publication number
NL300757I1
NL300757I1 NL300757C NL300757C NL300757I1 NL 300757 I1 NL300757 I1 NL 300757I1 NL 300757 C NL300757 C NL 300757C NL 300757 C NL300757 C NL 300757C NL 300757 I1 NL300757 I1 NL 300757I1
Authority
NL
Netherlands
Application number
NL300757C
Other languages
Dutch (nl)
Other versions
NL300757I2 (enExample
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300757(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NL300757I1 publication Critical patent/NL300757I1/nl
Publication of NL300757I2 publication Critical patent/NL300757I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
NL300757C 2000-09-05 2015-08-28 NL300757I2 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Publications (2)

Publication Number Publication Date
NL300757I1 true NL300757I1 (enExample) 2015-12-29
NL300757I2 NL300757I2 (enExample) 2015-12-29

Family

ID=24630250

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300757C NL300757I2 (enExample) 2000-09-05 2015-08-28

Country Status (25)

Country Link
US (7) US6414016B1 (enExample)
EP (2) EP1857105B1 (enExample)
JP (3) JP2004508327A (enExample)
KR (2) KR100901102B1 (enExample)
CN (1) CN100335049C (enExample)
AR (2) AR030609A1 (enExample)
AT (1) ATE476975T1 (enExample)
AU (2) AU2001282615B2 (enExample)
BR (1) BRPI0114042B8 (enExample)
CA (1) CA2419741C (enExample)
CZ (1) CZ304740B6 (enExample)
DE (2) DE60142810D1 (enExample)
DK (2) DK1857105T3 (enExample)
ES (2) ES2347697T3 (enExample)
HU (1) HU229319B1 (enExample)
IL (2) IL154534A0 (enExample)
MX (1) MXPA03001959A (enExample)
NL (1) NL300757I2 (enExample)
NO (1) NO332701B1 (enExample)
NZ (1) NZ524401A (enExample)
PT (2) PT1315485E (enExample)
RU (1) RU2694361C3 (enExample)
TW (1) TWI305147B (enExample)
WO (1) WO2002020007A1 (enExample)
ZA (1) ZA200301673B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402925T2 (de) * 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
RU2392941C2 (ru) * 2004-09-02 2010-06-27 Сукампо Аг Производные простагландинов для лечения желудочно-кишечного нарушения
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
JP5147404B2 (ja) 2005-01-27 2013-02-20 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
AU2006219152B2 (en) 2005-03-04 2011-02-24 Sucampo Ag Method and composition for treating peripheral vascular diseases
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR101466980B1 (ko) * 2005-04-12 2014-12-01 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자펌프 억제제의 병용
BRPI0707333B8 (pt) 2006-01-24 2021-05-25 R Tech Ueno Ltd composição farmacêutica que compreende um composto bicíclico, método de estabilização do composto bicíclico e formulação de cápsula de gelatina mole
CA2637797C (en) * 2006-02-07 2015-03-17 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
PT2349250T (pt) * 2008-10-31 2017-07-25 Lipid Pharmaceuticals Ehf Ácidos gordos para uso como um medicamento
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
WO2011091513A1 (en) 2010-01-28 2011-08-04 Apotex Pharmachem Inc. Polymorphic forms of lubiprostone
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20170020890A1 (en) * 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
WO2018193572A1 (ja) * 2017-04-20 2018-10-25 株式会社島津製作所 分光光度計
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (enExample) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
EP0310305B1 (en) 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
DE69130586T2 (de) * 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
ATE402925T2 (de) * 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
ES2252286T3 (es) * 2000-07-14 2006-05-16 Henkel Kommanditgesellschaft Auf Aktien Cuerpos huecos con compartimentos, que contienen una porcion de detergente textil, de limpieza lavavajillas.
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
NO20030996L (no) 2003-05-02
US20030216465A1 (en) 2003-11-20
MXPA03001959A (es) 2003-06-24
RU2694361C2 (ru) 2019-07-12
AU8261501A (en) 2002-03-22
EP1857105B1 (en) 2010-08-11
DE60131547T2 (de) 2008-10-23
KR20030029919A (ko) 2003-04-16
NZ524401A (en) 2004-08-27
NO332701B1 (no) 2012-12-10
US20120237598A1 (en) 2012-09-20
ZA200301673B (en) 2003-11-26
BR0114042A (pt) 2003-07-22
JP2004508327A (ja) 2004-03-18
CA2419741C (en) 2010-11-30
IL154534A0 (en) 2003-09-17
ES2347697T3 (es) 2010-11-03
EP1857105A2 (en) 2007-11-21
JP4684334B2 (ja) 2011-05-18
HUP0302422A2 (hu) 2003-10-28
DK1315485T3 (da) 2008-03-03
DE60131547D1 (de) 2008-01-03
ATE476975T1 (de) 2010-08-15
KR100918223B1 (ko) 2009-09-21
ES2296786T3 (es) 2008-05-01
AU2001282615B2 (en) 2006-06-22
AR100291A2 (es) 2016-09-28
US6414016B1 (en) 2002-07-02
RU2694361C9 (ru) 2019-12-25
TWI305147B (en) 2009-01-11
US8071613B2 (en) 2011-12-06
NO20030996D0 (no) 2003-03-04
AR030609A1 (es) 2003-08-27
JP2009286806A (ja) 2009-12-10
US20030040528A1 (en) 2003-02-27
DE60142810D1 (de) 2010-09-23
PT1315485E (pt) 2008-01-23
DK1857105T3 (da) 2010-09-20
HUP0302422A3 (en) 2005-02-28
CN1655776A (zh) 2005-08-17
BRPI0114042B1 (pt) 2016-11-08
HU229319B1 (en) 2013-10-28
WO2002020007A1 (en) 2002-03-14
US8114890B1 (en) 2012-02-14
US8748454B2 (en) 2014-06-10
EP1315485A1 (en) 2003-06-04
PT1857105E (pt) 2010-10-08
US20140235665A1 (en) 2014-08-21
US20120022152A1 (en) 2012-01-26
CN100335049C (zh) 2007-09-05
IL154534A (en) 2010-04-29
NL300757I2 (enExample) 2015-12-29
EP1857105A3 (en) 2008-03-05
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
JP2009114217A (ja) 2009-05-28
CZ304740B6 (cs) 2014-09-17
CA2419741A1 (en) 2002-03-14
KR20080091278A (ko) 2008-10-09
BRPI0114042B8 (pt) 2021-05-25
EP1315485B1 (en) 2007-11-21
KR100901102B1 (ko) 2009-06-08
RU2694361C3 (ru) 2020-07-20

Similar Documents

Publication Publication Date Title
BE2013C060I2 (enExample)
BE2010C008I2 (enExample)
BE2011C032I2 (enExample)
BE2010C018I2 (enExample)
BE2011C041I2 (enExample)
BRPI0110940B8 (enExample)
JP2001135253A5 (enExample)
BE2010C040I2 (enExample)
JP2003517558A5 (enExample)
JP2003512536A5 (enExample)
JP2001094209A5 (enExample)
JP2003506745A5 (enExample)
JP2002118290A5 (enExample)
JP2001074791A5 (enExample)
JP2001076056A5 (enExample)
JP2002133694A5 (enExample)
JP2001338387A5 (enExample)
JP2001197361A5 (enExample)
BR0112866A2 (enExample)
JP2002310483A5 (enExample)
CN3145854S (enExample)
CN3144126S (enExample)
CN3147656S (enExample)
CN3146111S (enExample)
AM949A2 (enExample)